Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

NEW YORK, December 30, 2025, 1:54 PM ET — Regular session Genmab A/S’s U.S.-listed shares (GMAB) fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares changing hands. The move keeps attention on Genmab’s pipeline as investors reassess which late-stage assets can power growth. Dropping a late-stage program can change a biotech’s outlook quickly because those trials sit closest to potential approvals and revenue. Genmab said on Monday it will discontinue further clinical development of acasunlimab after a portfolio review, citing a more competitive landscape. “After
30 December 2025
·····
Lionsgate Studios (LION) stock slides today after insider sales hit the tape

Lionsgate Studios (LION) stock slides today after insider sales hit the tape

NEW YORK, December 30, 2025, 13:49 ET — Regular session Lionsgate Studios Corp shares fell 3.4% on Tuesday, retreating after filings showed two top executives sold stock late this month. The stock was down 32.5 cents at $9.105, after trading between $9.06 and $9.45. The disclosures landed with the stock near the top of its 52-week range of $5.55 to $9.46. That has made the name more sensitive to any sign of selling pressure heading into year-end. StockAnalysis Form 4 filings — mandatory SEC reports that disclose insider buying and selling — can move shares in the short term because
30 December 2025
·····
Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts

Energy Fuels stock falls today as UUUU pulls back after uranium sales beat, new contracts

NEW YORK, December 30, 2025, 13:43 ET — Regular session Shares of Energy Fuels Inc fell 3.5% to $14.55 in afternoon trading on Tuesday. The uranium miner lagged peers, with Uranium Energy down about 1.9% while Cameco was little changed and MP Materials slipped about 1.3%. Energy Fuels traded about 5.9 million shares and ranged between $14.30 and $15.28. The pullback matters because uranium stocks have been swinging on fresh evidence of supply discipline, contract signings and realized pricing. Investors want proof that producers can turn high commodity prices into durable cash flow, not just headlines. Energy Fuels is a
30 December 2025
·····
ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

ADMA Biologics stock slides nearly 4% as biotech weakens in thin year-end trade

NEW YORK, December 30, 2025, 13:35 ET — Regular session Shares of ADMA Biologics fell 3.7% to $18.40 in afternoon trading on Tuesday, a steeper drop than the broader biotech group. The SPDR S&P Biotech ETF was down about 1.3%. The pullback came as U.S. stocks steadied in holiday-thin trading ahead of minutes from the Federal Reserve’s December policy meeting, after the central bank delivered a 25-basis-point cut this month. Mark Hackett, chief market strategist at Nationwide, described recent positioning as “a healthy rebalancing of allocations.” Reuters Biotechnology shares were among the laggards, with the NYSE Arca Biotechnology Index down
30 December 2025
····
Rivian stock drops nearly 6% as CEO share-sale filing hits the tape in thin year-end trade

Rivian stock drops nearly 6% as CEO share-sale filing hits the tape in thin year-end trade

NEW YORK, December 30, 2025, 13:30 ET — Regular session Rivian Automotive, Inc shares were down about 6% on Tuesday, pulling back in a light year-end session after a regulatory filing disclosed a stock sale by Chief Executive Officer Robert J. Scaringe. The move matters because thin holiday liquidity can exaggerate swings in high-volatility names, and investors have shifted back to demand signals and funding risk across electric-vehicle makers. Traders also had one eye on U.S. Federal Reserve minutes due later in the session and a closely watched Tesla update on quarterly deliveries, events that can reset risk appetite for
30 December 2025
······
Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

NEW YORK, December 30, 2025, 13:38 ET — Regular session Shares of Mineralys Therapeutics Inc fell 3.3% to $35.61 by early afternoon on Tuesday, after touching a session low of $35.17. About 513,000 shares had changed hands, versus a previous close of $36.83. Mineralys has a market value of about $2.9 billion and remains up about 183% over the past 52 weeks, even after sliding about 25% from its 52-week high set in November. Analysts expect the company to stay loss-making in the near term; Barchart shows an average quarterly EPS estimate of -$0.57 and an expected next earnings date
30 December 2025
·····
Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus

NEW YORK, December 30, 2025, 13:33 ET — Regular session Rhythm Pharmaceuticals shares were down 4.2% at $107.85 at 1:33 p.m. ET on Tuesday, after trading as low as $106.65. The move matters because Rhythm is a single-product rare-disease biotech whose stock has tended to swing on regulatory and clinical milestones for Imcivree, its obesity drug. Investors are watching the company’s next U.S. Food and Drug Administration decision closely. With the next major catalyst still ahead, the stock can move sharply on broader risk sentiment in biotech, even when there is no fresh company news. The SPDR S&P Biotech ETF
30 December 2025
····
Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

Warby Parker stock price today: WRBY falls nearly 4% in thin year-end trading

NEW YORK, December 30, 2025, 13:34 ET — Regular session Warby Parker Inc (WRBY) shares fell about 3.9% to $22.11 in early afternoon trading on Tuesday, after ending Monday at $23.00. The stock opened at $22.90 and traded between $21.87 and $23.13, with nearly 3 million shares changing hands; the company is valued at about $3.4 billion. The slide comes with just a handful of sessions left in 2025, a stretch when trading often thins out and price moves can look outsized. Thin trading means fewer buyers and sellers, so routine position changes can move a stock more than usual.
30 December 2025
·····
France vows stable electricity bills in 2026 — but new charges could still push costs up

France vows stable electricity bills in 2026 — but new charges could still push costs up

NEW YORK, December 30, 2025, 13:17 ET France’s economy ministry says most households should not see their electricity bills rise in 2026 and 2027 as the country enters a new pricing regime for nuclear power from Jan. 1. L’Energeek The reassurance comes just ahead of the expiry of ARENH, a long-running scheme that capped the price of part of EDF’s nuclear output and helped set the benchmark for retail electricity offers. The change matters now because it lands at the start of a new year, when households reset budgets and energy bills are a politically sensitive issue after the volatility
30 December 2025
·
Vipshop stock slides about 5% today as Jefferies flags softer December trends ahead of Fed minutes

Vipshop stock slides about 5% today as Jefferies flags softer December trends ahead of Fed minutes

NEW YORK, December 30, 2025, 1:14 PM ET — Regular session Vipshop Holdings Limited (VIPS) shares fell about 5% on Tuesday, trading around $18.39 in afternoon dealings. The drop came in a muted U.S. session with year-end liquidity thin, leaving single-stock swings more pronounced than usual. Reuters Investors are also waiting for the Federal Reserve’s minutes from its Dec. 9-10 meeting due later Tuesday, looking for signals on how policymakers see the 2026 path for interest rates. Reuters Jefferies analyst Thomas Chong reiterated a buy rating and a $22.60 price target on Vipshop. Jefferies expects fourth-quarter revenue at the low
30 December 2025
····
Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

Corcept stock slides nearly 9% as FDA decision deadline arrives — what’s driving CORT today

NEW YORK, December 30, 2025, 13:14 ET — Regular session Corcept Therapeutics Inc shares fell 8.9% to $72.72 in early afternoon Nasdaq trading on Tuesday, after touching a session low of $72.26. The stock was last down $7.10 from Monday’s close, with about 897,000 shares traded. The decline comes as investors focus on Corcept on the day the U.S. Food and Drug Administration is due to decide on relacorilant, its experimental treatment for endogenous hypercortisolism, also known as Cushing’s syndrome. Under the Prescription Drug User Fee Act, or PDUFA, the FDA sets a target date for taking action on a
30 December 2025
·····
Equinox Gold stock climbs as gold rebounds — here’s what’s moving EQX today

Equinox Gold stock climbs as gold rebounds — here’s what’s moving EQX today

NEW YORK, December 30, 2025, 13:01 ET — Regular session Equinox Gold Corp shares rose about 2.2% on Tuesday, trading around $14.30, as a rebound in gold prices lifted the sector. The stock traded between $14.18 and $14.58, with about 2.2 million shares changing hands. The move matters because the gold market has turned choppy into year-end after a powerful run, and miners often magnify bullion swings. A small change in the gold price can quickly reshape expectations for miners’ cash flow. Investors are also positioning around the Federal Reserve’s December meeting minutes, due later Tuesday, for clues on how
30 December 2025
····
1 … 474 475 476 477 478 … 884

Stock Market Today

GSK share price set for Monday watch after EU clears Nucala COPD use

GSK share price set for Monday watch after EU clears Nucala COPD use

7 February 2026
GSK shares closed Friday up 0.83% at a 52-week high after the EU approved Nucala for certain uncontrolled COPD patients. Insider filings showed chairman Jonathan Symonds bought 2,500 shares while executive David Redfern sold 100,000. The FTSE 100 rose 0.6%. Broker ratings on GSK remained mixed.
Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

Aye Finance IPO: Rs 454-crore anchor haul follows valuation cut below last round

7 February 2026
Aye Finance raised Rs 454.5 crore from 19 anchor investors ahead of its Feb 9 IPO, pricing shares at the top of a Rs 122–129 range. The company’s profit fell 40% to Rs 64.3 crore in the six months to September as bad loans rose to 4.85%. The IPO values Aye at about Rs 3,200 crore, below its last private round. Major investors include Nippon Life India and Goldman Sachs funds.
BAT share price closes near 52-week high as buyback rolls on ahead of results week

BAT share price closes near 52-week high as buyback rolls on ahead of results week

7 February 2026
British American Tobacco shares closed up 1.2% at 4,609 pence Friday, near a 52-week high. The company disclosed further share buybacks and management share purchases ahead of its Feb. 12 full-year results. BAT bought 121,668 shares for cancellation on Feb. 5. Investors await updates on nicotine alternatives and cash returns.
Go toTop